Disorders A - Z:   A    B   C    D    E    F    G    H    I    J    K    L    M    N    O    P    Q    R    S    T    U    V    W    X    Y    Z

Skip secondary menu

Safety, Tolerability and Activity Study of Ibudilast in Subjects with Progressive Multiple Sclerosis (NN102/SPRINT-MS)



Eligibility Criteria:

Inclusion:

  • Male or female subjects ages 21 to 65
  • Confirmed diagnosis of secondary-progressive multiple sclerosis (SPMS) or primary progressive multiple sclerosis (PPMS) according to 2010 International Panel Criteria
  • Typical MS lesions on MRI according to Swanton's MRI
  • Expanded Disability Status Scale (EDSS) 3.0-6.5
  • Clinical evidence of disability progression in the preceding two years
  • Existing MS pharmacotherapy status may include interferon-beta or glatiramer acetate or none (i.e. untreated)
  • Females of child bearing potential must have a negative serum β-hCG at screening
  • Both males and females must be willing to use appropriate contraception for the duration of the study treatment and 30 days after the last dose of study treatment.
  • Subject is in good physical health on the basis of medical history, physical examination, and laboratory screening, as defined by the investigator.

Exclusion:

  • Progressive neurological disorder other than SPMS or PPMS
  • Relapse and/or systemic corticosteroid steroid treatment for MS within 3 months of screening.
  • Current use of intermittent systemic corticosteroids
  • Use of oral immunosuppressants within 6 months of screening
  • Use of mitoxantrone, natalizumab, or IVIg within 6 months of screening
  • Use of fingolimod or dimethyl fumarate [Tecfidera®] within 3 months of screening
  • Use of rituximab or other B-cell therapy within 12 months of screening
  • Current use of other MS disease-modifying therapies (DMTs) besides glatiramer acetate, IFNβ-1 (any formulation), and the above listed medications.
  • Current use of cimetidine, cyclosporine, dronedarone, lopinavir, probenecid, quinidine (including Neudexta), ranolazine, rifampin, ritonavir, or tipranavir.
  • Clinically significant cardiovascular disease, including myocardial infarct within last 6 months, unstable ischemic heart disease, congestive heart failure or angina
  • Resting pulse < 50 bpm, sinoatrial (SA) or atrioventricular (AV) block, uncontrolled hypertension, or QTcF > 450 ms
  • Clinically significant pulmonary conditions, including severe chronic obstructive pulmonary disease (COPD), fibrosis, or tuberculosis
  • Evidence of acute hepatitis, clinically significant chronic hepatitis, or evidence of clinically significant impaired hepatic function through clinical and laboratory evaluation
  • Immune system disease (other than MS and autoimmune thyroid disease)
  • History of stomach or intestinal surgery or any other condition that could interfere with or is judged by the Investigator to interfere with absorption, distribution, metabolism, or excretion of study drug
  • Any significant laboratory abnormality which, in the opinion of the Investigator, may put the subject at risk and with the following laboratory abnormalities at screening:
    • Creatinine: females > 0.95 mg/dL; males > 1.17 mg/dL
    • WBCs < 3,000 mm3
    • Lymphocytes < 800 mm3
    • Platelets < 90,000 mm3
  • History of malignancy < 5 years prior to signing the informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
  • History of HIV (human immunodeficiency virus), clinically significant chronic hepatitis, or other active infection.
  • Subject currently has a clinically significant medical condition (other than MS)
    Note: Active medical conditions that are minor or well-controlled are not exclusionary if, in the judgment of the investigator, they do not affect risk to the subject or the study results.
  • Subjects with moderate to severe depression as determined by the Beck Depression Inventory-Fast Screen (BDI-FS)
  • Subject has a history of alcohol or substance abuse within 3 months prior to screening or alcohol or substance dependence within 12 months prior to screening
  • Subject has poor peripheral venous access that will limit the ability to draw blood as judged by the Investigator
  • Subject is currently participating, or has participated in, a study with an investigational or marketed compound or device within 3 months prior to signing the informed consent
  • Subject is unable to undergo MRI imaging because of having an artificial heart valve, metal plate, pin, or other metallic objects (including gun shots or shrapnel) in their body or is unable to complete all the five MRI scans required for this study.
  • Subject is unable to lie sufficiently still in an MRI to obtain a high quality MRI image.



Last updated July 18, 2014